FDA Approves Afrezza Inhaled Insulin for Children
The regulatory agency authorized the use of inhaled insulin for pediatric patients aged 6 and older in May 2026.
Updated on Oct. 26, 2026 in Asthma
Live Poll
Do you believe new medical technology is the most important factor in improving quality of life?
In May 2026, the FDA granted approval for the use of Afrezza, an inhaled insulin powder, for children as young as 6 years old. The device delivers insulin directly into the lungs and bloodstream in under one minute, offering an alternative to traditional needles.
Why it matters
This approval provides a needle-free delivery option for pediatric patients, potentially reducing the pain and social stigma associated with insulin injections. It represents a significant expansion of access for younger individuals managing diabetes.
Afrezza is available in cartridges containing 4, 8, or 12 units of insulin. The inhaler system delivers the medication into the bloodstream in less than one minute.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
The details
The medication is administered via an inhaler but is strictly contraindicated for individuals with asthma, as well as smokers and vapers. While the delivery method simplifies administration, it does not serve as a replacement for basal insulin therapy.
Timeline
The FDA approved the pediatric use of Afrezza in May 2026.
Manufacturer financial assistance for the medication is available through December 2026.
Health Landscape
This development aligns with standard FDA drug approval protocols for expanding established therapeutic options to pediatric populations. It reflects a broader shift toward optimizing insulin delivery systems to improve treatment compliance among children.
Patients and their families may utilize the manufacturer's financial assistance program through the end of 2026. Prospective users must be screened to ensure they do not have asthma, as the drug is prohibited for those with this condition.
The takeaway
Families should consult with their healthcare provider to determine if the needle-free inhaler is a safe and suitable option for their child. It is critical to adhere to all safety warnings, particularly regarding respiratory health and the exclusion of smokers or those with asthma.
What happens next
The manufacturer-provided financial assistance program is set to conclude in December 2026.
Further reading
For more information on respiratory health and medication guidelines, visit the Asthma section.
Source note: This article includes information reported by NBC Chicago.
Live Poll
Do you believe new medical technology is the most important factor in improving quality of life?
